\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Month Year

Month Year

Get News Alerts by Email

Feb 13, 2012

Trovagene Appoints Charlie Rodi, Ph.D., as Chief Technology Officer
Feb 9, 2012

Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Feb 7, 2012

Trovagene Closes Acquisition of CLIA Laboratory Assets
Jan 5, 2012

TrovaGene Acquires CLIA - Certified Laboratory
Jan 2, 2012

TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia

License Complements Franchise of the Company's Proprietary Tumor Marker Assets in Hematological Cancers

Show per page